Clinical Trial

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-01.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07209410
Lead Sponsor Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Conditions Glaucoma
Enrollment 35 participants
Start Date 2025-11-01
Primary Completion 2026-12-15 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-18